Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California.
- SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California.
- Below is the list of accepted abstracts, with links to each:
Title: Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers
Title: Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine